~ 102811 Combating Age-Related Brain Deterioration - References

References

1. Bugg JM, Head D. Exercise moderates age-related atrophy of the medial temporal lobe. Neurobiol Aging. 2011 Mar;32(3):506-14.

2. Alzheimer's Association. 2009 Alzheimer's disease facts and figures. Alzheimers Dement. 2009 May;5(3):234-70.

3. Pavlović DM, Pavlović AM. Mild cognitive impairment. Srp Arh Celok Lek. 2009 Jul-Aug;137(7-8):434-9.

4. Pike KE, Savage G. Memory profiling in mild cognitive impairment: can we determine risk for Alzheimer's disease? J Neuropsychol. 2008 Sep;2(Pt 2):361-72.

5. Swartz RH, Stuss DT et al. Independent cognitive effects of atrophy and diffuse subcortical and thalamico-cortical cerebrovascular disease in dementia. Stroke. 2008 Mar;39(3):822-30.

6. Braverman ER, Chen TJ, Prihoda TJ, et al. Plasma growth hormones, P300 event-related potential and test of variables of attention (TOVA) are important neuroendocrinological predictors of early cognitive decline in a clinical setting: evidence supported by structural equation modeling (SEM) parameter estimates. Age (Dordr). 2007 Sep;29(2-3):55-67.

7. Dahl A, Hassing LB, et al. Being overweight in midlife is associated with lower cognitive ability and steeper cognitive decline in late life. J Gerontol A Biol Sci Med Sci. 2010 Jan;65(1):57-62.

8. Raji CA, Ho AJ, et al. Brain structure and obesity. Hum Brain Mapp. 2010 Mar;31(3):353-64.

9. Geiger BM, Behr GG, et al. Evidence for defective mesolimbic dopamine exocytosis in obesity-prone rats. FASEB J. 2008 Aug;22(8):2740-6.

10. Geiger BM, Haburcak M, et al. Deficits of mesolimbic dopamine neurotransmission in rat dietary obesity. Neuroscience. 2009 Apr 10;159(4):1193-9.

11. Margolin D, Hammerstad J, Orwoll E, McClung M, Calhoun D. Intracranial calcification in hyperparathyroidism associated with gait apraxia and parkinsonism. Neurology. 1980 Sep;30(9):1005-7.

12. Bilge I, Sadikoĝlu B, Emre S, Sirin A, Tatli B. Brain calcification due to secondary hyperparathyroidism in a child with chronic renal failure. Turk J Pediatr. 2005 Jul-Sep;47(3):287-90.

13. Vidal JS, Sigurdsson S, Jonsdottir MK, et al. Coronary artery calcium, brain function and structure: the AGES-Reykjavik Study. Stroke. 2010 May;41(5):891-7.

14. Lui LY, Stone K, Cauley JA, Hillier T, Jaffe K. Bone loss predicts subsequent cognitive decline in older women: the study of osteoporotic fractures. J Am Geriatr Soc. 2003 Jan; 51(1):38-43.

15. Braverman ER, Chen TJ, Chen AL, et al. Age-related increases in parathyroid hormone may be antecedent to both osteoporosis and dementia. BMC Endocr Disord. 2009 Oct 13;9:21.

16. Farrag AK, Khedr EM, et al. Effect of surgical menopause on cognitive functions. Dement Geriatr Cogn Disord. 2002;13(3):193-8.

17. Blum K, Sheridan PJ, Wood RC, et al. The D2 dopamine receptor gene as a determinant of reward deficiency syndrome. J R Soc Med. 1996 Jul;89(7):396-400.

18. Blum K, Chen AL, Chen TJ, et al. Activation instead of blocking mesolimbic dopaminergic reward circuitry is a preferred modality in the long term treatment of reward deficiency syndrome (RDS): a commentary. Theor Biol Med Model. 2008 Nov 12;5:24.

19. Blum K, Braverman ER, Holder JM, et al. Reward deficiency syndrome: a biogenetic model for the diagnosis and treatment of impulsive, addictive, and compulsive behaviors. J Psychoactive Drugs. 2000 Nov;32 Suppl:i-iv, 1-112.

20. Dowling GJ, Weiss SR, Condon TP. Drugs of abuse and the aging brain. Neuropsychopharmacology. 2008 Jan;33(2):209-18.

21. Colliver JD, Compton WM, Gfroerer JC, Condon T. Projecting drug use among aging baby boomers in 2020. Ann Epidemiol. 2006 Apr;16(4):257-65.

22. Pedraza C, García FB, Navarro JF. Neurotoxic effects induced by gammahydroxybutyric acid (GHB) in male rats. Int J Neuropsychopharmacol. 2009 Oct;12(9):1165-77.

23. Lecacheux M, Karila L, et al. Cognitive modifications associated with tobacco smoking. Presse Med. 2009 Sep;38(9):1241-52.

24. Banakar MK, Kudlur NS, George S. Fetal alcohol spectrum disorder (FASD). Indian J Pediatr. 2009 Nov;76(11):1173-5.

25. Loeber S, Duka T, Welzel H, et al. Impairment of cognitive abilities and decision making after chronic use of alcohol: the impact of multiple detoxifications. Alcohol Alcohol. 2009 Jul-Aug;44(4):372-81.

26. Majewska MD. Cocaine addiction as a neurological disorder: implications for treatment. NIDA Res Monogr. 1996;163:1-26.

27. Karila L, Lowenstein W, Coscas S, Benyamina A, Reynaud A. Complications of cocaine addiction. Rev Prat. 2009 Jun 20;59(6):825-9.

28. Jager G, Ramsey NF. Long-term consequences of adolescent cannabis exposure on the development of cognition, brain structure and function: an overview of animal and human research. Curr Drug Abuse Rev. 2008 Jun;1(2):114-23.

29. Indlekofer F, Piechatzek M, Daamen M, et al. Reduced memory and attention performance in a population-based sample of young adults with a moderate lifetime use of cannabis, ecstasy and alcohol. J Psychopharmacol. 2009 Jul;23(5):495-509.

30. Gruber SA, Silveri MM, Yurgelun-Todd DA. Neuropsychological consequences of opiate use. Neuropsychol Rev. 2007 Sep;17(3):299-315.

31. Cadet JL, Krasnova IN. Molecular bases of methamphetamine-induced neurodegeneration. Int Rev Neurobiol. 2009;88:101-19.

32. Available at: http://www.cdc.gov/ncipc/pub-res/tbi_in_us_04/tbi_ed.htm. Accessed July 12, 2011.

33. Langlois J, Rutland-Brown W, Wald M. The epidemiology and impact of traumatic brain injury: A brief overview. J Head Trauma Rehab. 2006;21(5):375-8.

34. Ainslie PN, Cotter JD, George KP, et al. Elevation in cerebral blood flow velocity with aerobic fitness throughout healthy human ageing. J Physiol. 2008 Aug 15;586(16):4005-10.

35. Deslandes A, Moraes H, Ferreira C, et al. Exercise and mental health: many reasons to move. Neuropsychobiology. 2009;59(4):191-8.

36. Crawford JG. Alzheimer's disease risk factors as related to cerebral blood flow. Med Hypotheses. 1996 Apr;46(4):367-77.

37. Geda YE, Roberts RO, Knopman DS, et al. Physical exercise, aging, and mild cognitive impairment: a population-based study. Arch Neurol. 2010 Jan;67(1):80-6.

38. Baker LD, Frank LL, Foster-Schubert K, et al. Effects of aerobic exercise on mild cognitive impairment: a controlled trial. Arch Neurol. 2010 Jan;67(1):71-9.

39. Clark PJ, Brzezinska WJ, Puchalski EK, Krone DA, Rhodes JS. Functional analysis of neurovascular adaptations to exercise in the dentate gyrus of young adult mice associated with cognitive gain. Hippocampus. 2009 Oct;19(10):937-50.

40. Van Praag H. Neurogenesis and exercise: past and future directions. Neuromolecular Med. 2008;10(2):128-40.

41. Fabel K, Kempermann G. Physical activity and the regulation of neurogenesis in the adult and aging brain. Neuromolecular Med. 2008;10(2):59-66.

42. Lautenschlager NT, Cox KL, Flicker L, et al. Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease: a randomized trial. JAMA. 2008 Sep 3;300(9):1027-37.

43. Garraux G. Preserve brain function...through physical exercice? Rev Med Liege. 2008 May-Jun;63(5-6):293-8.

44. Ma Q. Beneficial effects of moderate voluntary physical exercise and its biological mechanisms on brain health. Neurosci Bull. 2008 Aug;24(4):265-70.

45. Lange-Asschenfeldt C, Kojda G. Alzheimer's disease, cerebrovascular dysfunction and the benefits of exercise: from vessels to neurons. Exp Gerontol. 2008 Jun;43(6):499-504.

46. Linkis P, Jřrgensen LG, Dynamic exercise enhances regional cerebral artery mean flow velocity. J Appl Physiol. 1995 Jan;78(1):12-6.

47. Yaffe K, Fiocco AJ, et al. Predictors of maintaining cognitive function in older adults: the Health ABC study. Neurology. 2009 Jun 9;72(23):2029-35.

48. Reichman WE. Nondegenerative dementing disorders. In: Coffey CE, Cummings JL, eds. The American Psychiatric Press Textbook of Geriatric Neuropsychiatry. 2nd ed. Washington, DC: American Psychiatric Press; 2000:491-507.

49. Braverman ER. Younger You: Unlock the Hidden Power of Your Brain to Look and Feel 15 Years Younger. New York, NY:mcgraw-Hill; 2006.

50. Lista I, Sorrentino G. Biological mechanisms of physical activity in preventing cognitive decline. Cell Mol Neurobiol. 2010 May;30(4):493-503.

51. Cotman CW, Berchtold NC. Exercise: a behavioral intervention to enhance brain health and plasticity. Trends Neurosci. 2002 Jun;25(6):295-301.

52. Komulainen P, Pedersen M, Hanninen T, et al. BDNF is a novel marker of cognitive function in ageing women: the DR's EXTRA Study. Neurobiol Learn Mem. 2008 Nov;90(4):596-603.

53. Van der Borght K, Kóbor-Nyakas DE, Klauke K, et al. Physical exercise leads to rapid adaptations in hippocampal vasculature: temporal dynamics and relationship to cell proliferation and neurogenesis. Hippocampus. 2009 Oct;19(10):928-36.

54. Pereira AC, Huddleston DE, Brickman AM, et al. An in vivo correlate of exercise-induced neurogenesis in the adult dentate gyrus. Proc Natl Acad Sci U S A. 2007 Mar 27;104(13):5638-43.

55. Balu DT, Lucki I. Adult hippocampal neurogenesis: regulation, functional implications, and contribution to disease pathology. Neurosci Biobehav Rev. 2009 Mar;33(3):232-52.

56. Elder GA, De Gasperi R, Gama Sosa MA. Research update: neurogenesis in adult brain and neuropsychiatric disorders. Mt Sinai J Med. 2006 Nov;73(7):931-40.

57. Paizanis E, Kelaď S, Renoi T, Hamon T, Lanfumey L. Life-long hippocampal neurogenesis: environmental, pharmacological and neurochemical modulations. Neurochem Res. 2007 Oct;32(10):1762-71.

58. Lee E, Son H. Adult hippocampal neurogenesis and related neurotrophic factors. BMB Rep. 2009 May 31;42(5):239-44.

59. Eisch AJ, Cameron HA, et al. Adult neurogenesis, mental health, and mental illness: hope or hype? J Neurosci. 2008 Nov 12;28(46):11785-91.

60. Kempermann G, Krebs J, Fabel K. The contribution of failing adult hippocampal neurogenesis to psychiatric disorders. Curr Opin Psychiatry. 2008 May;21(3):290-5.

61. Paizanis E, Kelai S, Renoir T, Hamon M, Lanfumey L. Life-long hippocampal neurogenesis: environmental, pharmacological and neurochemical modulations. Neurochem Res. 2007 Oct;32(10):1762-71.

62. Lazarov O, Mattson MP, Peterson DA, Pimplikar SW, van Praag H. When neurogenesis encounters aging and disease. Trends Neurosci. 2010 Dec;33(12):569-79.

63. Meerlo P, Mistlberger RE, et al. New neurons in the adult brain: the role of sleep and consequences of sleep loss. Sleep Med Rev. 2009 Jun;13(3):187-94.

64. Querido JS, Sheel AW. Regulation of cerebral blood flow during exercise. Sports Med. 2007;37(9):765-82.

65. Ploughman M. Exercise is brain food: the effects of physical activity on cognitive function. Dev Neurorehabil. 2008 Jul;11(3):236-40.

66. Floel A, Ruscheweyh R, Kruger K, et al. Physical activity and memory functions: Are neurotrophins and cerebral gray matter volume the missing link? Neuroimage. 2010 Feb 1;49(3):2756-63.

67. Takechi R, Galloway S, Pallebage-Gamarallage MM, Lam V, Mamo JC. Dietary fats, cerebrovasculature integrity and Alzheimer's disease risk. Prog Lipid Res. 2009 Nov 5.

68. Lee Y, Back JH, Kim J. Systematic review of health behavioral risks and cognitive health in older adults. Int Psychogeriatr. 2010 Mar;22(2):174-87.

69. Pasinetti GM, Eberstein JA. Metabolic syndrome and the role of dietary lifestyles in Alzheimer's disease. J Neurochem. 2008 Aug;106(4):1503-14.

70. Sofi F, Cesari F, Abbate R, Gensini GF, Casini A. Adherence to Mediterranean diet and health status: meta-analysis. BMJ. 2008 Sep 11;337:a1344.

71. Cole GM, Frautschy SA. DHA may prevent age-related dementia. J Nutr. 2010 Apr;140(4):869-74.

72. Shah K, Qureshi SU, Johnson M, Parikh M, Shulz PE, Kunik ME. Does use of antihypertensive drugs affect the incidence or progression of dementia? A systematic review. Am J Geriatr Pharmacother. 2009 Oct;7(5):250-61.

73. Castro JE, Varea E, Marquez C, Cordero MI, Poirier G, Sandi C. Role of the amygdala in antidepressant effects on hippocampal cell proliferation and survival and on depression-like behavior in the rat. PLoS One. 2010 Jan 8;5(1):e8618.

74. Boldrini M, Underwood MD, Hen R, et al. Antidepressants increase neural progenitor cells in the human hippocampus. Neuropsychopharmacology. 2009 Oct;34(11):2376-89.


Free Shipping in the Continental U.S. on Orders over $50
The statements made here have not been evaluated by the FDA. The foregoing statements are based upon sound and reliable studies, and are meant for informational purposes. Consult with your medical practitioner to determine the underlying cause of your symptoms. Please always check your purchase for possible allergins and correct dosage on the bottle before use.

While we work to ensure that product information is correct, on occasion manufacturers may alter their ingredient lists. Actual product packaging and materials may contain more and/or different information than that shown on our Web site. We recommend that you do not solely rely on the information presented and that you always read labels, warnings, and directions before using or consuming a product. For additional information about a product, please contact the manufacturer. Content on this site is for reference purposes and is not intended to substitute for advice given by a physician, pharmacist, or other licensed health-care professional. You should not use this information as self-diagnosis or for treating a health problem or disease. Contact your health-care provider immediately if you suspect that you have a medical problem. Information and statements regarding dietary supplements have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease or health condition. Life Ex Online assumes no liability for inaccuracies or misstatements about products.